同时靶向RSK与AKT抑制乳腺癌细胞YB-1介导的DNA双链断裂修复
该临床前研究在三阴性乳腺癌(TNBC)与非TNBC细胞系及正常乳腺上皮MCF-10A中,探讨RSK抑制剂LJI308对YB-1 S102磷酸化、电离辐射诱导DNA双链断裂(DSB)修复及细胞存活的影响。结果显示LJI308仅部分抑制部分细胞系DSB修复,与PI3K依赖的AKT激活有关;同时靶向AKT和RSK可强烈阻断所有癌细胞系DSB修复,并在MDA-MB-231和MCF7中增加放射敏感性,对MCF-10A影响较小。提示同时靶向RSK与AKT可能有效阻断放疗后DSB修复并诱导乳腺癌细胞放射增敏。
要点
- LJI308抑制RSK(T359/S363)与YB-1(S102)磷酸化,但单药仅部分抑制部分细胞系DSB修复。
- 单药效果受限与PI3K依赖的AKT激活或AKT组成性活性有关,正常MCF-10A细胞不明显。
- 同时靶向AKT和RSK强烈阻断所有癌细胞系DSB修复,并增强MDA-MB-231与MCF7放射敏感性。
核心结论
- 同时靶向RSK和AKT可能是阻断照射后DSB修复并诱导乳腺癌细胞放射增敏的有效策略。
研究设计与样本
- 临床前细胞研究,使用TNBC细胞系MDA-MB-231、MDA-MB-468、Hs 578T,非TNBC细胞系MCF7、HBL-100、SKBR3,以及正常乳腺上皮MCF-10A细胞。
- 采用RSK抑制剂LJI308、药理抑制剂或siRNA处理,通过Western blotting检测通路激活,γH2AX焦点试验评估DSB修复,标准克隆形成试验评估照射后细胞存活。
主要发现
- LJI308在照射后、EGF处理后及KRAS突变细胞中抑制RSK(T359/S363)和YB-1(S102)磷酸化。
- LJI308仅在某些受试细胞系中轻度抑制DSB修复,归因于PI3K依赖的AKT刺激或AKT组成性活性,主要见于癌细胞而非正常MCF-10A细胞。
- 同时靶向AKT和RSK强烈阻断所有癌细胞系的DSB修复,与TNBC状态或KRAS突变无关,对MCF-10A细胞影响较小。
- 同时靶向RSK和AKT在TNBC MDA-MB-231和非TNBC MCF7细胞中诱导放射敏感性,但在MCF-10A细胞中未诱导。
临床怎么用
- 在乳腺癌放疗中,单靶向RSK可能因AKT代偿激活而疗效有限,需考虑同时抑制RSK与AKT以增强放射敏感性。
- 该策略在TNBC与非TNBC细胞系中均显示阻断DSB修复和放射增敏作用,且对正常乳腺上皮细胞影响较小,但尚未进入临床。
局限性
- 研究仅基于细胞系体外实验,未提供动物模型或临床数据。
- 同时靶向RSK和AKT的正常组织毒性及治疗窗需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Y-box binding protein 1 (YB-1) overexpression is associated with chemotherapy- and radiation therapy resistance. Ionizing radiation (IR), receptor tyrosine kinase ligands, and mutation in KRAS gene stimulate activation of YB-1. YB-1 accelerates the repair of IR-induced DNA double-strand breaks (DSBs). Ribosomal S6 kinase (RSK) is the main kinase inducing YB-1 phosphorylation. We investigated the impact of RSK targeting on DSB repair and radiosensitivity. MATERIALS AND METHODS: The triple negative breast cancer (TNBC) cell lines MDA-MB-231, MDA-MB-468, and Hs 578T, in addition to non-TNBC cell lines MCF7, HBL-100, and SKBR3, were used. MCF-10A cells were included as normal breast epithelial cells. The RSK inhibitor LJI308 was used to investigate the role of RSK activity in S102 phosphorylation of YB-1 and YB-1-associated signaling pathways. The activation status of the underlying pathways was investigated by Western blotting after treatment with pharmacologic inhibitors or transfection with siRNA. The impact of LJI308 on DSB repair and postirradiation cell survival was tested by the γH2AX foci and the standard clonogenic assays, respectively. RESULTS: LJI308 inhibited the phosphorylation of RSK (T359/S363) and YB-1 (S102) after irradiation, treatment with EGF, and in cells expressing a KRAS mutation. LJI308 treatment slightly inhibited DSB repair only in some of the cell lines tested. This was shown to be due to PI3K-dependent stimulation of AKT or constitutive AKT activity mainly in cancer cells but not in normal breast epithelial MCF-10A cells. Simultaneous targeting of AKT and RSK strongly blocked DSB repair in all cancer cell lines, independent of TNBC status or KRAS mutation, with a minor effect in MCF-10A cells. Cotargeting of RSK- and AKT-induced radiation sensitivity in TNBC MDA-MB-231 and non-TNBC MCF7 cells but not in MCF-10A cells. CONCLUSIONS: Simultaneous targeting of RSK and AKT might be an efficient approach to block the repair of DSBs after irradiation and to induce radiosensitization of breast cancer cells.
引用
- Lettau K, Zips D, Toulany M, et al. Simultaneous Targeting of RSK and AKT Efficiently Inhibits YB-1-Mediated Repair of Ionizing Radiation-Induced DNA Double-Strand Breaks in Breast Cancer Cells. Int J Radiat Oncol Biol Phys. 2020. PMID: 32931865. doi:10.1016/j.ijrobp.2020.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。